With the attention that the breast cancer drug Herceptin has received in recent months, non-sufferers could almost be forgiven for wondering if this is a catch-all cure for the disease. But in spite of everyone having heard of it, under what circumstances is Herceptin the right drug? Who should patients listen to for information about their treatment? And what responsibility do drug companies have in informing the public about their products?
Jenni is joined by Kasia Boddy, a patient now receiving Herceptin treatment, Professor John Toy, an oncologist for Cancer Research UK and Joanne Shaw, chairs Datapharm, an industry-led organisation providing information on drugs to the public.
Breast Cancer Care:0808 800 6000 BBC Actionline: 0800 044 044
